Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation
Authors:
- 1 February 2017
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 97 (2) , 270-277
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialThe Lancet Oncology, 2013
- Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group ProjectJournal of Clinical Oncology, 2011
- Response, survival, and toxicity after iodine‐131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adultsCancer, 2011
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task ForceBritish Journal of Cancer, 2010
- Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experienceJournal of Pediatric Surgery, 2010
- The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of ageEuropean Journal of Cancer, 2008
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999